4D Molecular Therapeutics, Inc. SEC filings FDMT

4D Molecular Therapeutics, Inc. has 439 filings in SEC EDGAR's recent list, going back to Aug 13, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 28, 2026 —
DEF 14A Proxy statement Apr 28, 2026 Jun 17, 2026
DEFA14A Additional proxy material Apr 29, 2025 —
DEF 14A Proxy statement Apr 29, 2025 Jun 17, 2025
DEFA14A Additional proxy material Apr 10, 2024 —
DEF 14A Proxy statement Apr 10, 2024 May 21, 2024
DEFA14A Additional proxy material Apr 12, 2023 —
DEF 14A Proxy statement Apr 12, 2023 May 23, 2023
DEFA14A Additional proxy material Apr 13, 2022 —
DEF 14A Proxy statement Apr 13, 2022 May 23, 2022
DEFA14A Additional proxy material Apr 6, 2021 —
DEF 14A Proxy statement Apr 6, 2021 May 17, 2021

Showing 12 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
FDMT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Emeryville, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1650648
Former names
4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.